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Cancer family history has been known to be one of the
main risk factors. Members of high – risk families should
be given recommendations, which may improve prophy-
laxis, early diagnosis and treatment. At present time is pos-
sible to identify several genes involved in the hereditary
forms of some types of cancers including colorectal and
breast/ovarian. Hereditary forms of breast cancer are
mostly caused by mutations in such genes as BRCA1/2
and of hereditary non-polyposis colorectal cancer in genes
HLMH1, HMSH2 or HMSH6. Previous studies of Lithua-
nian population concentrated on breast/ovarian cancer
families identified three recurrent mutations 4153delA,
5382insC and C61G in BRCA1 gene. Later studies of unse-
lected cases breast and ovarian cancer patients found that
6% of breast and 19% of ovarian cancer carried a founder
mutation in the BRCA1 gene. The majority of mutation-
positive patients did not have a significant family history:
71.4 % of the breast cancer patients and 87.5% of the ovar-
ian. These and others clinical genetic aspects raise a neces-
sity to change view on routine cancer prevention strategy,
as mammography screening for breast cancer with
BRCA1/2 mutations, screening by IFOBT and colonoscopy
for HPCC and it is necessary to change the view on combi-
nation of chemotherapy (including neo-adjuvant) with
BRCA1 positive breast cancer (anthracyclines/taxans).
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